Morgan puts the broader incretin market, which includes GLP-1s across both obesity and diabetes, at $200 billion by 2030, with approximately 25 million Americans on GLP-1 treatment by then, up from around 10 million in 2025
Instead, the standard treatment is a weekly injection for diabetes and weight loss
Liposomal and other enhanced-delivery forms are specifically designed to work around that absorption barrier, and small studies support that they generally outperform plain glutathione
Front Public Health Volume 82020 Grewal K, Lee YS, Smith A, Brosens JJ, Bourne T, Al-Memar M, Kundu S, MacIntyre DA, Bennett PR (2022) Chromosomally normal miscarriage is associated with vaginal dysbiosis and local inflammation
Coffee polyphenol consumption improves postprandial hyperglycemia associated with impaired vascular endothelial function in healthy male adults